Boris Peaker is ranked #2151 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

JONE

Boris Peaker

Q: How accurate are Boris Peaker's stock ratings?

About 54% of Boris's ratings were profitable over a one-year hold, with an average return of +12.7% per rating, measured by 13Foresight from historical prices.

JonesTrading

Wall Street Analyst

★★★☆☆

#2151

on 13Foresight · ranked by our own returns

55%

Success Rate

+27.8%

Average Return

59 of 108 calls profitable · +12.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 55% of Boris Peaker's ratings turned a profit when each position was held for 2 year — averaging +27.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

85 Buy 23 Hold 0 Sell

Boris's Stock Coverage 73 ratings · 2026-08-30

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
ELTX Elicio Therapeutics	Aug 17, 2026	HOLD	Buy +538.2% avg upside 11 analysts	—	+0.7%	·
ANL Adlai Nortye Ltd. Sponsored ADR	Aug 14, 2026	BUY	Strong Buy +56.3% avg upside 7 analysts	$22.00 59.15% Upside	+8.1%	·
AVBP ArriVent BioPharma, Inc.	Aug 12, 2026	BUY	Strong Buy +40.6% avg upside 15 analysts	$45.00 49.21% Upside	-3.9%	·
BOLT Bolt Biotherapeutics	Aug 12, 2026	HOLD	Buy +581.5% avg upside 7 analysts	—	+10.6%	·
MNPR Monopar Therapeutics Inc	Aug 12, 2026	BUY	Strong Buy -7.3% avg upside 18 analysts	$130.00 16.28% Upside	-3.5%	·
TARA Protara Therapeutics	Aug 11, 2026	BUY	Strong Buy +1245.0% avg upside 21 analysts	$25.00 554.45% Upside	+2.1%	·
BCAX Bicara Therapeutics Inc.	Aug 11, 2026	BUY	Strong Buy +36.2% avg upside 15 analysts	$30.00 28.08% Upside	+0.6%	·
ATYR aTyr Pharma	Aug 10, 2026	HOLD	Buy +1453.0% avg upside 17 analysts	—	+4.9%	·
CRVO CervoMed	Aug 10, 2026	BUY	Strong Buy +607.2% avg upside 9 analysts	$12.00 361.61% Upside	-7.7%	·
INAB IN8bio	Aug 07, 2026	BUY	Strong Buy +5697.1% avg upside 5 analysts	$5.00 383.03% Upside	+30.8%	·
JANX Janux Therapeutics Inc	Aug 07, 2026	BUY	Strong Buy +151.2% avg upside 22 analysts	$28.00 55.24% Upside	+9.7%	·
RLAY Relay Therapeutics	Aug 07, 2026	BUY	Strong Buy +18.6% avg upside 21 analysts	$20.00 6.50% Upside	-1.8%	·
WHWK Whitehawk Therapeutics	Aug 06, 2026	BUY	Strong Buy +169.0% avg upside 14 analysts	$7.00 51.43% Upside	+8.1%	·
CGON CG Oncology, Inc.	Aug 06, 2026	BUY	Strong Buy +15.5% avg upside 17 analysts	$85.00 14.36% Upside	-0.7%	·
PRME Prime Medicine, Inc.	Aug 06, 2026	BUY	Strong Buy +164.6% avg upside 17 analysts	$5.00 38.41% Upside	+23.4%	·
CNTX Context Therapeutics	Aug 06, 2026	BUY	Strong Buy +1262.5% avg upside 12 analysts	$2.00 421.26% Upside	-23.8%	·
CGEM Cullinan Management	Aug 06, 2026	BUY	Strong Buy +58.2% avg upside 15 analysts	$36.00 65.89% Upside	+25.9%	·
NUVB Nuvation Bio	Aug 06, 2026	BUY	Strong Buy +99.2% avg upside 17 analysts	$12.00 80.14% Upside	+13.5%	·
ELVN Enliven Therapeutics	Aug 06, 2026	BUY	Strong Buy +3.1% avg upside 16 analysts	$70.00 21.01% Upside	+0.4%	·
ACET Adicet Bio	Aug 06, 2026	BUY	Strong Buy +179.6% avg upside 14 analysts	$20.00 120.68% Upside	+14.2%	·
OKUR OnKure Therapeutics	Aug 05, 2026	HOLD	Buy +483.1% avg upside 13 analysts	—	-7.9%	·
EDIT Editas Medicine	Aug 05, 2026	BUY	Buy +329.4% avg upside 33 analysts	$8.00 153.11% Upside	+13.1%	·
ORIC Oric Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy +80.3% avg upside 19 analysts	$25.00 88.82% Upside	+3.3%	·
TYRA Tyra Bioscience	Aug 04, 2026	BUY	Strong Buy +78.4% avg upside 17 analysts	$56.00 124.55% Upside	-23.3%	·
FTH Faeth Therapeutics	Aug 04, 2026	BUY	Strong Buy +35.3% avg upside 17 analysts	$55.00 62.49% Upside	+32.3%	·
BEAM Beam Therapeutics	Aug 04, 2026	BUY	Strong Buy +77.4% avg upside 25 analysts	$35.00 19.47% Upside	+7.5%	·
CRIS Curis	Jul 29, 2026	BUY	Strong Buy +779.8% avg upside 12 analysts	$20.00 1242.36% Upside	-69.9%	·
ONCY Oncolytics Biotech	Jul 13, 2026	HOLD	Strong Buy +685.1% avg upside 12 analysts	—	-8.6%	·
ALT Altimmune	Feb 13, 2026	BUY	Strong Buy +763.1% avg upside 20 analysts	$7.00 125.01% Upside	-28.5%	·
MGNX MacroGenics	Jun 03, 2024	HOLD	Buy +329.8% avg upside 25 analysts	—	-6.2%	·
IRWD Ironwood Pharma	Jan 12, 2024	HOLD	Buy +187.1% avg upside 23 analysts	$10.50 154.28% Upside	-63.2%	·
EBS Emergent Biosolutions	Jan 12, 2024	HOLD	Buy +323.0% avg upside 9 analysts	$5.00 15.35% Downside	+504.4%	·
LNTH Lantheus	Dec 18, 2023	BUY	Buy -19.6% avg upside 21 analysts	$83.00 17.63% Downside	+16.6%	·
URGN Urogen Pharma	Dec 05, 2023	BUY	Strong Buy +6.6% avg upside 16 analysts	—	+73.7%	·
AU:TLX Telix Pharmaceuticals	Dec 04, 2023	BUY	Strong Buy +61.9% avg upside 14 analysts	$16.00 2.15% Upside	+51.9%	·
STRO Sutro Biopharma	Nov 16, 2023	BUY	Strong Buy +101.3% avg upside 21 analysts	—	-61.7%	·
HRTX Heron Therapeutics	Nov 15, 2023	BUY	Strong Buy +8728.4% avg upside 21 analysts	$2.50 665.50% Upside	+27.9%	·
CELC Celcuity	Nov 13, 2023	BUY	Strong Buy +37.8% avg upside 16 analysts	—	+689.7%	·
NKTR Nektar Therapeutics	Nov 09, 2023	BUY	Buy +5.7% avg upside 26 analysts	—	+677.4%	·
TCRX TScan Therapeutics	Nov 09, 2023	BUY	Strong Buy +1028.8% avg upside 12 analysts	—	-74.7%	·
IMA ImageneBio	Nov 09, 2023	BUY	Buy +235.1% avg upside 13 analysts	—	-48.1%	·
ADCT ADC Therapeutics	Nov 09, 2023	HOLD	Buy +353.2% avg upside 12 analysts	—	+763.2%	·
XNCR Xencor	Nov 07, 2023	BUY	Strong Buy +32.7% avg upside 27 analysts	—	-25.0%	·
CTMX CytomX Therapeutics	Nov 07, 2023	HOLD	Strong Buy +236.0% avg upside 21 analysts	—	+182.8%	·
PCVX Vaxcyte	Nov 06, 2023	BUY	Strong Buy +74.0% avg upside 15 analysts	—	-13.6%	·
CBIO Crescent Biopharma	Nov 03, 2023	BUY	Strong Buy +25.5% avg upside 17 analysts	—	-90.8%	·
PCRX Pacira Pharmaceuticals	Nov 02, 2023	BUY	Buy +52.8% avg upside 21 analysts	$50.00 94.02% Upside	-26.8%	·
GB:0DPB Bavarian Nordic AS	Jul 20, 2022	BUY	Strong Buy +64.7% avg upside 5 analysts	$433.00 102.82% Upside	-39.5%	·
MRK Merck & Company	Jun 27, 2022	HOLD	Strong Buy -8.4% avg upside 43 analysts	$102.00 31.20% Downside	+45.2%	·
NCNA Nucana	Mar 03, 2022	HOLD	Buy +615.9% avg upside 9 analysts	—	·	·
IOVA Iovance Biotherapeutics	Mar 25, 2020	BUY	Strong Buy +65.2% avg upside 25 analysts	—	-44.0%	·
SE:ONCO Oncopeptides AB	Mar 20, 2020	BUY	Hold 2 analysts	—	·	·
ARGX Argenx Se	Aug 01, 2019	BUY	Strong Buy -18.9% avg upside 47 analysts	—	+110.6%	·
EXEL Exelixis	Jan 14, 2019	BUY	Buy -20.8% avg upside 34 analysts	—	+4.0%	·
CLDX Celldex	Nov 12, 2018	HOLD	Strong Buy +4.4% avg upside 28 analysts	—	+291.2%	·
CRVS Corvus Pharmaceuticals	Nov 11, 2018	BUY	Strong Buy +79.6% avg upside 14 analysts	—	-45.1%	·
TLPH Talphera	Aug 01, 2017	HOLD	Buy +292.7% avg upside 15 analysts	—	·	·
BVNRY Bavarian Nordic	May 05, 2017	BUY	Strong Buy 3 analysts	—	·	·
FATE Fate Therapeutics	Nov 04, 2015	BUY	Buy +398.6% avg upside 31 analysts	—	+1.1%	·
MDGL Madrigal Pharmaceuticals	Oct 21, 2015	HOLD	Strong Buy -6.0% avg upside 33 analysts	—	+73.8%	·
LITS Lite Strategy	Oct 07, 2015	BUY	Buy +1009.1% avg upside 13 analysts	—	·	·
SLS SELLAS Life Sciences Group	Nov 23, 2014	HOLD	Strong Buy +422.9% avg upside 16 analysts	—	·	·
INCY Incyte	Aug 20, 2014	BUY	Buy -12.2% avg upside 48 analysts	$75.00 39.69% Downside	+47.3%	·
OPK Opko Health	May 12, 2014	BUY	Buy +354.9% avg upside 12 analysts	$12.00 710.85% Upside	+13.6%	·
AMGN Amgen	Apr 23, 2014	HOLD	Buy -25.9% avg upside 57 analysts	$122.00 71.86% Downside	+50.0%	·
NWBO Northwest Biotherapeutics	Mar 12, 2014	HOLD	Hold +2537.1% avg upside 1 analyst	$5.00 2537.09% Upside	·	·
STAB Statera BioPharma	Jan 24, 2014	HOLD	Hold +749900.0% avg upside 1 analyst	$0.75 749900.03% Upside	·	·
FBIO Fortress Biotech	Jan 03, 2014	HOLD	Strong Buy +185.2% avg upside 12 analysts	—	+0.4%	·
VCEL Vericel	Mar 27, 2013	HOLD	Strong Buy +12.8% avg upside 16 analysts	—	-73.5%	·
PLX Protalix	Mar 19, 2013	BUY	Buy +228.0% avg upside 4 analysts	$7.00 175.49% Upside	·	·
TSE:CSCI COSCIENS Biopharma	Aug 16, 2012	HOLD	Strong Buy +128.7% avg upside 8 analysts	—	·	·
CORT Corcept Therapeutics	Mar 27, 2012	BUY	Strong Buy -41.5% avg upside 16 analysts	$9.00 92.03% Downside	-3.0%	·
PLUR Pluri	May 17, 2011	BUY	Strong Buy +291.7% avg upside 8 analysts	$5.00 226.84% Upside	·	·

🔒 68 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Boris Peaker — Frequently Asked Questions

How accurate are Boris Peaker's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Boris's ratings were profitable over a one-year hold, with an average return of +12.7% per rating, or +3.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Boris ranked on 13Foresight?

Boris Peaker is currently ranked #2151 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Boris cover?

Boris most recently has ratings on ELTX, ANL, AVBP, BOLT, MNPR, TARA, BCAX, ATYR, CRVO, INAB, JANX, RLAY and 61 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Boris Peaker

Rating Distribution

Welcome to 13Foresight!